Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results from Phase 3 EMPOWER-Lung 3 Part 2 Trial

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Expert reviews favorable efficacy and durability 5-year results for cemiplimab plus chemotherapy versus chemotherapy in the EMPOWER-Lung 3 Part 2 trial. 